Bulk Pharmaceutical API Sources for OSELTAMIVIR PHOSPHATE

Bulk Pharmaceutical API Sources for OSELTAMIVIR PHOSPHATE

Vendor	Vendor Homepage	Vendor Sku	API Url
Molport		MolPort-005-938-626
Oakwood Products		069081
Amadis Chemical		A4307
BioChemPartner		BCPP000138
BioChemPartner		BCP9001033

OSELTAMIVIR PHOSPHATE Bulk API Sourcing Landscape

Last updated: February 19, 2026

This report analyzes the global sourcing landscape for bulk Oseltamivir Phosphate Active Pharmaceutical Ingredient (API). Key findings include the dominant role of Chinese manufacturers, the presence of Indian suppliers, and the impact of supply chain disruptions on pricing and availability. Patent expiry and regulatory hurdles are significant factors influencing market dynamics.

What is the Global Production Capacity for Oseltamivir Phosphate API?

Global production capacity for Oseltamivir Phosphate API is concentrated among a limited number of manufacturers, primarily in Asia. While precise aggregate capacity figures are not publicly disclosed, industry estimates suggest that production is sufficient to meet current global demand, with some buffer for seasonal influenza outbreaks.

• Primary Production Hubs: China and India are the principal manufacturing centers.
• Key Manufacturers: Several Chinese companies, including those in the Yangtze River Delta region, represent a substantial portion of global capacity. Indian pharmaceutical companies also contribute to supply.
• Capacity Fluctuations: Production levels can be scaled up or down based on anticipated demand, particularly during influenza season.

The manufacturing process for Oseltamivir Phosphate API is complex, involving multiple synthetic steps. This complexity, coupled with the need for specialized equipment and stringent quality control, limits the number of companies capable of large-scale, cost-effective production.

Who are the Key Manufacturers of Oseltamivir Phosphate API?

The market for Oseltamivir Phosphate API is characterized by a mix of established generic API producers and specialized chemical manufacturers.

Table 1: Identified Oseltamivir Phosphate API Manufacturers (Sample)

Manufacturer Name	Country of Origin	Primary Business Focus	Notes
Zhejiang NHU Co., Ltd.	China	API & Fine Chemicals	Large-scale producer with integrated manufacturing capabilities. Holds multiple DMFs.
Anhui BBCA Pharmaceutical Co., Ltd.	China	APIs, Pharmaceutical Intermediates	Significant player in the Chinese API market. Focus on bulk production.
NCPC Pharmaceutical Group Co., Ltd.	China	Pharmaceuticals & APIs	Major Chinese pharmaceutical conglomerate with substantial API production capacity.
Shandong Xinhua Pharmaceutical Co., Ltd.	China	APIs & Formulations	Long-standing pharmaceutical company with a broad API portfolio, including Oseltamivir Phosphate.
IOL Chemicals and Pharmaceuticals Limited	India	APIs, Specialty Chemicals	Indian manufacturer with a growing presence in global API markets. Actively seeking DMF filings.
Divi's Laboratories Limited	India	APIs, Intermediates	Major Indian API producer, known for large-scale manufacturing. While not always explicitly listed for Oseltamivir Phosphate, has the capability for complex synthesis.
Shanghai Pharma Co., Ltd.	China	Pharmaceuticals & APIs	Diversified pharmaceutical group with API manufacturing subsidiaries.

These manufacturers typically operate under Good Manufacturing Practices (GMP) and often hold Drug Master Files (DMFs) with regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

What are the Patent Expiries and Regulatory Considerations for Oseltamivir Phosphate?

The patent landscape for Oseltamivir Phosphate is a critical factor influencing market entry and competition. The primary patents covering Oseltamivir Phosphate have expired in major markets, opening the door for generic competition.

• Original Patent Holder: Hoffmann-La Roche (now Roche) held the original patents for Oseltamivir Phosphate.
• Patent Expiry: Key composition of matter patents expired in the United States and Europe around 2016-2018. Method of use patents may have different expiry dates.
• Generic Entry: Following patent expiries, numerous generic manufacturers have entered or sought to enter the market for Oseltamivir Phosphate API and finished dosage forms.
• Regulatory Filings: Manufacturers must obtain regulatory approval from relevant health authorities to supply Oseltamivir Phosphate API. This typically involves submitting a DMF to agencies like the FDA or EMA. The approval process can be lengthy and resource-intensive.
• Quality Standards: API suppliers must adhere to strict GMP guidelines. Audits by regulatory bodies and customers are common. Compliance with pharmacopoeial standards (e.g., USP, EP) is mandatory.
• Supply Chain Security: Regulatory agencies are increasingly focused on the security and integrity of the pharmaceutical supply chain, including API sourcing. This involves assessing the manufacturing processes, quality control, and risk management of API suppliers.

The expiry of foundational patents has led to a more competitive pricing environment for Oseltamivir Phosphate API. However, the technical complexities of synthesis and the rigorous regulatory requirements maintain a barrier to entry for new suppliers.

What are the Supply Chain Risks and Mitigation Strategies?

The Oseltamivir Phosphate API supply chain faces several risks that can impact availability and pricing.

Table 2: Supply Chain Risks for Oseltamivir Phosphate API

Risk Category	Specific Risks	Impact
Geopolitical & Trade	Trade disputes, tariffs, export restrictions from key manufacturing countries (e.g., China).	Increased costs, delays, potential shortages if primary suppliers are inaccessible.
Regulatory Changes	Stricter environmental regulations in manufacturing countries leading to temporary shutdowns or increased compliance costs. Changes in import/export controls for chemical intermediates.	Production halts, increased operational expenses, delays in product release.
Quality & Compliance	Non-compliance with GMP standards leading to batch rejections or import alerts. Contamination issues.	Disruption of supply, reputational damage for the supplier, significant financial loss for the buyer.
Logistical Challenges	Shipping delays due to port congestion, natural disasters, or global transport disruptions (e.g., pandemics).	Extended lead times, potential spoilage of temperature-sensitive materials, increased inventory holding costs.
Raw Material Volatility	Fluctuations in the price and availability of key chemical intermediates required for Oseltamivir Phosphate synthesis.	Increased API cost, potential for production slowdowns if critical intermediates are scarce.
Single Sourcing	Over-reliance on a single manufacturer or region for supply.	Extreme vulnerability to any disruption affecting that specific supplier or region.

Mitigation Strategies:

• Dual Sourcing: Engaging with multiple qualified suppliers across different geographic regions to reduce reliance on any single source.
• Supplier Audits and Qualification: Conducting thorough quality and compliance audits of potential and existing suppliers. Establishing robust qualification processes.
• Inventory Management: Maintaining strategic safety stocks of API and critical intermediates, balancing holding costs against risk of stock-out.
• Contractual Agreements: Negotiating clear terms and conditions with suppliers, including force majeure clauses and supply guarantees.
• Geographic Diversification: Actively seeking and qualifying suppliers in different countries to mitigate regional risks.
• Supply Chain Visibility: Implementing systems for real-time tracking of shipments and supplier performance.
• Partnerships with Logistics Providers: Working with experienced and reliable third-party logistics providers.

Proactive risk management is essential for pharmaceutical companies relying on Oseltamivir Phosphate API.

What are the Pricing Trends for Oseltamivir Phosphate API?

Pricing for Oseltamivir Phosphate API is influenced by several factors, including manufacturing costs, raw material prices, supply and demand dynamics, regulatory compliance costs, and the competitive landscape.

• Post-Patent Expiry: Following the expiry of key patents, the market has seen increased competition from generic API manufacturers, which generally drives down prices.
• Manufacturing Location: API sourced from China and India typically offers a cost advantage compared to suppliers in Western countries, primarily due to lower labor and overhead costs.
• Volume Discounts: Larger purchase volumes generally result in lower per-unit pricing. Long-term supply agreements can also secure more favorable pricing.
• Quality and Compliance Premiums: APIs from manufacturers with strong regulatory track records and high-quality certifications may command a premium.
• Seasonal Demand: Demand for Oseltamivir Phosphate increases significantly during influenza seasons, which can lead to temporary price increases or upward pressure on pricing.
• Raw Material Costs: Fluctuations in the cost of key starting materials and chemical intermediates directly impact API manufacturing costs and, consequently, the final API price.
• Currency Exchange Rates: As a significant portion of API production is in Asia, exchange rate fluctuations between major currencies (e.g., USD, EUR) and local currencies (e.g., CNY, INR) can affect landed costs for buyers in other regions.

Indicative Pricing (As of Late 2023/Early 2024): Pricing can vary widely based on quality, quantity, and supplier. However, indicative bulk pricing for Oseltamivir Phosphate API has been observed in the range of $150 - $400 USD per kilogram. This range is subject to considerable volatility. Smaller, non-GMP batches or non-registered suppliers may offer lower prices but carry higher risks.

Key Takeaways

• China is the dominant supplier of Oseltamivir Phosphate API, with India emerging as a significant secondary source.
• The expiry of foundational patents has intensified generic competition and put downward pressure on API prices.
• Supply chain risks, including geopolitical factors, regulatory changes, and quality compliance issues, necessitate robust mitigation strategies such as dual sourcing and rigorous supplier qualification.
• Pricing is highly sensitive to manufacturing location, volume, regulatory compliance, and raw material costs, with a broad range observed in the market.
• Securing a reliable and compliant supply of Oseltamivir Phosphate API requires diligent supplier due diligence and proactive risk management.

FAQs

What is the typical lead time for Oseltamivir Phosphate API orders?

Typical lead times for Oseltamivir Phosphate API orders can range from 4 to 12 weeks, depending on the supplier's current production schedule, the size of the order, and existing inventory levels. Rush orders may be accommodated at an additional cost.

Are there any specific environmental regulations affecting Oseltamivir Phosphate API production?

Yes, environmental regulations, particularly in China, have become increasingly stringent. Manufacturers must comply with standards related to wastewater treatment, air emissions, and solid waste disposal. Non-compliance can lead to production halts and increased operational costs, impacting API availability and price.

How can I verify the GMP compliance of an Oseltamivir Phosphate API supplier?

Verification of GMP compliance can be achieved through several methods: requesting copies of recent GMP certificates, reviewing audit reports from regulatory agencies (e.g., FDA inspection reports), conducting on-site audits of the manufacturing facility, and obtaining Certificates of Analysis (CoAs) for product batches that demonstrate adherence to pharmacopoeial standards.

What are the key chemical intermediates used in Oseltamivir Phosphate synthesis, and are they prone to supply disruptions?

Key intermediates in Oseltamivir Phosphate synthesis include shikimic acid or its precursors (though some routes bypass direct shikimic acid reliance), 3-pentanone, and various amine and ester derivatives. The supply of these intermediates can be subject to disruption based on their own production complexities, raw material availability, and the environmental compliance of their manufacturers.

What is the difference between an API supplier with a US DMF and one with an EU CEP?

A US Drug Master File (DMF) is a submission to the U.S. Food and Drug Administration (FDA) containing detailed information about the manufacturing of a drug substance. An EU Certificate of Suitability to the monographs of the European Pharmacopoeia (CEP) is issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM) and certifies that the quality of a substance is suitably controlled by the relevant European Pharmacopoeia monograph. Both are critical for regulatory approval in their respective regions, but they represent different regulatory pathways and documentation requirements.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drug Master Files. Retrieved from [FDA website]

[2] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Certificates of Suitability (CEP). Retrieved from [EDQM website]

[3] Industry market reports and data from pharmaceutical intelligence providers (Specific report titles are proprietary and not publicly available for citation).

[4] Pharmaceutical company annual reports and public filings (Various, accessible via company investor relations websites).